Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. Issue 9 (2nd September 2018)

• Record Type: Journal Article
• Authors: Huang, Yunda; Karuna, Shelly; Carpp, Lindsay N.; Reeves, Daniel; Pegu, Amarendra; Seaton, Kelly; Mayer, Kenneth; Schiffer, Joshua; Mascola, John; Gilbert, Peter B.
• Is Part Of: Human vaccines & immunotherapeutics. Volume 14:Issue 9(2018)
• Page Start: 2116
• Page End: 2127
• Publication Date: 2018-09-02
• Subjects: Antibody Mediated Prevention Trial -- broadly neutralizing antibody -- non-human primate challenge study -- population pharmacokinetics -- statistical modeling of HIV prevention efficacy -- VRC01; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2018.1462640
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: The Antibody Mediated Prevention trials are assessing whether intravenously-administered VRC01 (10 mg/kg or 30 mg/kg vs placebo) can prevent HIV infection. In a modeling exercise, we used two models to predict the overall prevention efficacy (PE) of each VRC01 dose in preventing HIV infection. For the first per-exposure PE model, parameters were estimated from studies where nonhuman primates (NHPs) were administered high-dose intra-rectal simian-human immunodeficiency virus challenge two days post-VRC01 infusion at various dosages ("NHP model"). To account for the fact that humans may require greater VRC01 concentration to achieve the same level of protection, we next assumed that a 5-fold greater VRC01 serum concentration would be needed to provide the same level of per-exposure PE as seen in the NHP data ("5-fold model"). For the 10 mg/kg regimen, the 5-fold and NHP models predict an overall PE of 37% and 64%, respectively; for the 30 mg/kg regimen, the two models predict an overall PE of 53% and 82%, respectively. Our results support that VRC01 may plausibly confer positive PE in the AMP trials. Given the lack of available knowledge and data to verify the assumptions undergirding our modeling framework, its quantitative predictions of overall PE are preliminary. Its current main applications are to supplement decisions to advance mAb regimens to efficacy trials, and to enable mAb regimen ranking by their potential for PE in humans.